About me

Address: New York: One Bryant Park, Bank of America Tower, New York, NY 10036-6745

Areas of Focus: Tax; International Tax; Investment Management & Transactional Tax; Mergers & Acquisitions; Hedge Funds; Real Estate & Infrastructure Funds; Energy & Natural Resources Funds; Royalty Monetization; Joint Ventures & Strategic Alliances; Private Client & Family Office Services; Evergreen Funds

Biography:
David advises clients on the tax aspects of investment structures and business transactions with an emphasis on cross-border planning, domestic and international mergers & acquisitions (M&A), joint ventures and partnerships.
Serving as lead tax counsel, David routinely represents large, multinational, multi-strategy alternative investment fund managers on the U.S. and international tax aspects of their investments and transactions. David represents global asset managers spanning the spectrum of funds, including private equity funds, private credit funds, hedge funds, secondary funds, hybrid funds, evergreen funds, family offices, royalty funds, fund of funds and real estate funds.
David regularly assists clients in the structuring and restructuring of domestic and international investments and negotiating corporate acquisitions in both the domestic and cross-border contexts.
Clients rely on David for bespoke tax structures tailored to his clients’ investment strategies and business objectives. In addition, David represents fund managers on upper-tier structuring and transactions. David also represents clients, including funds and fund managers, in connection with complex tax controversies and other contentious tax matters.

Representative Work:
- Representing numerous global asset managers in serving as lead tax counsel on fund formations, investments, transactions and operations worldwide.
- Representing leading alternative investment managers in advising on planning and negotiating domestic and international business transactions, corporate and financial tax counseling.
- Represented ProKidney, a leading clinical-stage cellular therapeutics company focused on chronic kidney disease, in its $2.64 billion business combination with Social Capital Suvretta Holdings Corp. III.
- Represented Royalty Pharma plc on its $2.5 billion IPO and listing on the Nasdaq Global Select Market.
- Represented TPG Angelo Gordon in the fundraising of AG Asset Based Credit Fund LP with more than $1 billion of equity commitments. The fund received significant support from existing Angelo Gordon clients, as well as new institutional investors attracted to the firm’s demonstrated ability to generate value through private credit strategies globally.

Credentials:
Education: LL.M., New York University School of Law, 2010; J.D., University of Miami School of Law, 2009 (magna cum laude); B.A., University of Pennsylvania, 2006 (cum laude)
Bar Admissions: New York, 2010

Recognitions:
-

Affiliations:
-

Insights:
- Akin Advises Pharmakon Advisors on Debt Financing for ARCHIMED’s Up to $1.1 Billion Acquisition of Esperion Therapeutics (July 22, 2026): https://www.akingump.com/en/insights/press-releases/akin-advises-pharmakon-advisors-on-debt-financing-for-archimeds-up-to-dollar11-billion-acquisition-of-esperion-therapeutics
- Akin Advises Pharmakon Advisors in $200 Million Term Loan Facility for Kestra Medical Technologies (July 15, 2026): https://www.akingump.com/en/insights/press-releases/akin-advises-pharmakon-advisors-in-dollar200-million-term-loan-facility-for-kestra-medical-technologies
- Akin Advises Pharmakon Advisors on CHF 250 Million Term Loan to Idorsia Ltd (June 26, 2026): https://www.akingump.com/en/insights/press-releases/akin-advises-pharmakon-advisors-on-chf-250-million-term-loan-to-idorsia-ltd
- Akin Advises Pharmakon Advisors in $500 Million Senior Secured Term Loan to Mineralys Therapeutics (June 11, 2026): https://www.akingump.com/en/insights/press-releases/akin-advises-pharmakon-advisors-in-dollar500-million-senior-secured-term-loan-to-mineralys-therapeutics
- Fifth Circuit Overrules Tax Court, Providing Major Victory for Limited Partners on Self-Employment Tax (January 26, 2026): https://www.akingump.com/en/insights/alerts/fifth-circuit-overrules-tax-court-providing-major-victory-for-limited-partners-on-self-employment-tax
- Akin Advises Paine Schwartz Partners in Sale of AgBiTech to BASF Agricultural Solutions (January 20, 2026): https://www.akingump.com/en/insights/press-releases/akin-advises-paine-schwartz-partners-in-sale-of-agbitech-to-basf-agricultural-solutions
- Akin Advises Paine Schwartz Partners and HGS BioScience in Acquisition of Pharmgrade (January 13, 2026 ): https://www.akingump.com/en/insights/press-releases/akin-advises-paine-schwartz-partners-and-hgs-bioscience-in-acquisition-of-pharmgrade
- New Section 892 Regulations: Action Points for Private Fund Sponsors and Non-U.S. Pension Plan & Sovereign Investors (December 24, 2025): https://www.akingump.com/en/insights/alerts/new-section-892-regulations-action-points-for-private-fund-sponsors-and-non-us-pension-plan-and-sovereign-investors
- Akin Advises Metalor Technologies in Acquisition of Gannon & Scott (October 30, 2025): https://www.akingump.com/en/insights/press-releases/akin-advises-metalor-technologies-in-acquisition-of-gannon-and-scott
- Akin Advises Paine Schwartz Partners and HGS BioScience in Acquisition of NutriAg Ltd. (October 23, 2025): https://www.akingump.com/en/insights/press-releases/akin-advises-paine-schwartz-partners-and-hgs-bioscience-in-acquisition-of-nutriag-ltd
- Akin Advises Pharmakon in its Up to $500 Million Debt Facility Financing for Valneva SE  (October 8, 2025): https://www.akingump.com/en/insights/press-releases/akin-advises-pharmakon-in-its-up-to-dollar500-million-debt-facility-financing-for-valneva-se
- Akin Advises Pharmakon in its Up to $125 Million Credit Facility for Precigen (September 5, 2025): https://www.akingump.com/en/insights/press-releases/akin-advises-pharmakon-in-its-up-to-dollar125-million-credit-facility-for-precigen